Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America | Zendy

Zoe Moodie | Zendy; Michal Juraska | Zendy; Ying Huang | Zendy; Yingying Zhuang | Zendy; Youyi Fong | Zendy; Lindsay N. Carpp | Zendy; Steven G. Self | Zendy; Laurent Chambonneau | Zendy; Robert J. Small | Zendy; Nicholas Jackson | Zendy; Fernando Noriega | Zendy; Peter B. Gilbert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

Author(s) -

Zoe Moodie,

Michal Juraska,

Ying Huang,

Yingying Zhuang,

Youyi Fong,

Lindsay N. Carpp,

Steven G. Self,

Laurent Chambonneau,

Robert J. Small,

Nicholas Jackson,

Fernando Noriega,

Peter B. Gilbert

Publication year - 2017

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jix609

Subject(s) - dengue vaccine , dengue fever , medicine , serostatus , neutralizing antibody , serotype , immunogenicity , titer , virology , dengue virus , placebo , immunology , antibody , viral load , virus , alternative medicine , pathology

In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research